In contrast, melanoma patients with LAG3 expression in less than 1% of their immune cells had an average ORR of 5% (n = 22), indicating that LAG3 inhibition therapy may be a specific, targeted therapy for patients with high expression of LAG3 in their TME (Ascierto et al., 2017). This evidence concerns the gene LAG3 and melanoma.